Skip to main content

Information updates

Updated and new ASCIA HAE resources - January 2022

The ASCIA Hereditary Angioedema (HAE) Position Paper and Management Plan have been updated and are now available on the ASCIA website:

The urgent updating of these documents is due to Takhzyro® (lanadelumab) being PBS listed for HAE from 1st December 2021.

We have also taken this opportunity to make other product related changes, including:

  • Removal of the product name ‘Firazyr’ as the current product is generic ‘Icatibant’.
  • A statement regarding Danazol (Azol) being discontinued in January 2020 in Australia.
  • Replacing the Berinert® order form with an updated version on page 25.  
  • Updating of the ASCIA HAE Management Plan on page 23 to include Takhzyro® (lanadelumab) and remove the product name ‘Firazyr’.

A new ASCIA HAE Frequently Asked Questions (FAQ) for patients, consumers and carers has been developed in October 2021 and is available on the ASCIA website

This news item was issued on 13 January 2022 by ASCIA, the peak professional body for clinical immunology and allergy in Australia and New Zealand.